

**ORIGINAL**

**TSCA NON-CONFIDENTIAL BUSINESS INFORMATION**

DOCUMENT DESCRIPTION	DOCUMENT CONTROL NUMBER	DATE RECEIVED
8EHQ-10-17997	<b>88100000326</b>	6/15/10

COMMENTS:

**DOES NOT CONTAIN CBI**

327628



RECEIVED  
FBI/CED

10 JUN 15 AM 6:09

**AkzoNobel**  
Tomorrow's Answers Today

June 9, 2010

US EPA Office of Pollution Prevention and Toxics  
EPA East Building Room 6428  
Attn: Section 8(e)  
1201 Constitution Avenue, NW  
Washington, DC 20004

8EHQ-0610-17997A



**SUBJECT: TSCA 8(e) Notice**

Dear TSCA Section 8(e) Coordinator:

On behalf of Akzo Nobel Polymer Chemicals LLC, we are submitting interim study results of an OECD 429 Skin Sensitization: Local Lymph Node Assay on tert-butyl peroxybenzoate (CAS# 614-45-9) which was sponsored by Akzo Nobel Polymer Chemicals bv, Arkema France, Pergan GmbH and United Initiators GmbH & Co. KG.

Concentrations tested were vehicle, 25%, 50%, and 100%. The vehicle was dimethylformamide for the 25% and 50% concentrations.

The highest concentration where no signs of local irritation were reported during the study was 25%. The stimulation index for the LLNA exceeded the sensitization criterion value of 3 relative to the vehicle control for concentrations of the test article of 25% and higher.

No signs of systemic toxicity were observed.

Please contact me at (914) 333-7464 if you have any questions regarding this letter.

Sincerely,

  
John L. Orr, Ph.D., D.A.B.T., E.R.T.  
Expertise Leader Toxicology Americas  
Akzo Nobel Services Inc.  
Technology and Engineering  
Regulatory and Applied Life Sciences  
120 White Plains Road Suite 300  
Tarrytown, NY 10591

DCN: 88100000326



**CONTAINS NO CBI**




---


**AkzoNobel**  
Tomorrow's Answers Today

Copies to: Akzo Nobel Polymer Chemicals by  
Arkema France  
Pergan GmbH  
United Initiators GmbH & Co. KG

**CERTIFIED MAIL™**



7008 1830 0001 9257 9774



**Akzo Nobel Inc.**  
100 White Plains Road  
Suite 300  
Tarrytown, NY 10591-5322  
United States



**AkzoNobel**